Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ahrensburg – page 56

1 437 clinical trials in Ahrensburg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ahrensburg at a glance
1 437
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 437 trials in Ahrensburg

Open in trial search

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Cholangitis sclerosing

Not yet recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Duchenne muscular dystrophy+1

Not yet recruiting

Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Delandistrogene Moxeparvovec
  • Sponsor:Sarepta Therapeutics Inc.

Interstitial lung disease+1

Not yet recruiting

Study of tezepelumab in patients with progressive pulmonary fibrosis and increased eosinophil levels in blood

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:Philipps-Universitaet Marburg

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Nervous system disorder+1

Not yet recruiting

Study of KYV-101 Therapy for Patients with Refractory Primary and Secondary Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:KYV-101
  • Sponsor:Kyverna Therapeutics Inc.

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Acne

Not yet recruiting

Study on the Effectiveness and Safety of Clindamycin and Tretinoin Gel for Patients with Papulopustular Acne

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Clindamycin
  • Sponsor:Dermapharm AG

Dermatitis atopic

Not yet recruiting

Study on Eblasakimab for Adults with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Aslan Pharmaceuticals Pte Ltd

Chronic kidney disease

Not yet recruiting

Study on the Effects of Finerenone, Dapagliflozin, and Ambrisentan in Patients with Chronic Kidney Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ambrisentan
  • Sponsor:Steno Diabetes Center Copenhagen

Multiple sclerosis relapse

Not yet recruiting

Study on Ofatumumab Levels in Breast Milk of Women with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ahrensburg

What the registry says about research in the country

01 Respiratory Diseases

Innovative research focusing on asthma management and treatment, particularly examining new therapeutic approaches for patients with uncontrolled conditions. Studies are evaluating novel compounds to reduce exacerbation risks and improve symptom control.

  • Uncontrolled Asthma Studies
  • Gene Expression Analysis
  • Treatment Safety Evaluation

Multiple trials investigating both established and experimental treatments to enhance respiratory function and quality of life.

02 Pulmonary Conditions

Comprehensive studies addressing COPD and bronchiectasis, investigating new treatment modalities and their effects on exercise parameters and pulmonary function. Research includes assessment of dynamic hyperinflation and inflammatory responses.

  • Bronchiectasis Management
  • COPD Treatment Innovation
  • Exercise Performance Studies

Focus on developing targeted therapies for chronic respiratory conditions.

03 Specialized Respiratory Care

Advanced research into pulmonary fibrosis and allergic conditions, including long-term treatment evaluations and immunotherapy approaches. Studies examine safety profiles and efficacy of new therapeutic agents.

  • Pulmonary Fibrosis Treatments
  • Allergic Rhinitis Studies
  • Immunotherapy Research

Investigating innovative solutions for complex respiratory conditions requiring specialized care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.